Maxygen, Sanofi Pasteur ink $24.5M vaccine deal

Maxygen has agreed to transfer a portfolio of preclinical dengue antigens to Sanofi Pasteur for use developing a second generation vaccine. Maxygen stands to gain up to $24.5 million in the deal. The dengue virus afflicts more than 50 million people worldwide. About a week ago Maxygen announced that it is closing its facility in Denmark in a cost-cutting move.

- check out the release on the deal
- here's the AP report on Maxygen

ALSO: Take a look at Sanofi's pipeline. Report

Related Articles:
New tech drives huge growth in vaccine business. Report
New approach to vaccine development. Report
Vaccine "renaissance" attracts huge new venture investments. Report
Roche drops out of dev deal with Maxygen. Report